FDA Brief

Warning letters Drugs

FDA warning letter to

Cosmetic Science Laboratories LLC

High riskIssued Mar 10, 2023Posted Mar 21, 2023Division of Pharmaceutical Quality Operations IV

FDA warned Cosmetic Science Laboratories about OTC sunscreen drugs made without required manufacturing controls.

What happened

FDA inspected the Torrance, California drug manufacturing facility from September 6 to September 20, 2022, and found failures in identity testing, process validation, batch records, cleaning validation, water monitoring, and quality oversight. FDA also found the firm had not updated its drug establishment registration or met drug listing obligations, and it reviewed the firm’s website on March 7, 2023, which still advertised drug contract manufacturing after the firm said it had ceased drug production.

What FDA found

  1. The firm did not test each incoming active ingredient for identity and relied on suppliers’ test sheets, called certificates of analysis, without validating the suppliers’ test results.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm lacked adequate written production and process controls, had incomplete batch records, and did not provide process validation or formal studies showing its manufacturing process consistently works.

    21 CFR 211.100(a) and 211.188
  3. The firm could not show cleaning validation or equipment qualification, used the same equipment for drugs and cosmetics, and lacked cleaning and usage logs for kettles and mixers.

    21 CFR parts 210 and 211
  4. The firm did not establish that its water system was adequately designed, controlled, maintained, and monitored, and did not show routine microbial testing of the water used in drug products.

    21 CFR parts 210 and 211
  5. The firm’s quality control unit, its quality oversight group, did not provide adequate oversight, and the firm could not provide documents for test results outside specifications, deviations, investigations, annual product review, or CGMP training.

    21 CFR 211.22
  6. The firm failed to submit updated establishment registration and failed to meet drug listing obligations, making the drugs misbranded, meaning illegal under the law because not properly listed.

    FD&C Act section 510; 21 CFR 207.17 and 207.41

What FDA wants

FDA tells the firm to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. It also asks the firm to clarify whether it will resume drug manufacturing, to notify FDA before resuming, and, if it resumes, to engage a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC sunscreen drugs from this contract manufacturer
  • contract manufacturers that also make cosmetics on drug equipment
  • companies that rely on supplier certificates of analysis for active ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk